Zydus Lifesciences Limited engages in the research, development, production, marketing, distribution, and sale of pharmaceutical products in India, the United States, and internationally. It operates through two segments: Pharmaceuticals and Consumer Products. It offers active pharmaceutical ingredients, finished dosage formulations, generics, specialty, biosimilars, vaccines, novel products, consumer wellness and animal health products under the Everyuth, Nutralite, SugarFree, Complan, Glucon-D, and Nycil brands. The company also provides a pipeline of biological products in the areas of oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology, and infectious illnesses, as well as in the therapeutic areas of pain management, neurology, metabolic disorder, and neurology. In addition, it engages in the investment, animal health and veterinary, pharmacy retail, and manpower supply and administration activities. Further, it develops and markets products for orthopa
| Current Price | ₹1,078.30 |
|---|---|
| Market Cap | ₹1,08,502 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 21.5 |
| Return on Equity | 18.32% |
| 52-Week Range | ₹835.50 – ₹1,115.50 |
| Beta (1Y) | 0.54 |
| Dividend Yield | 0.09% |
1. Pharmaceuticals-82.6% 2. Consumer Products-14.6% 3. Medical Technologies-2.9%
Zydus Lifesciences Ltd is trading at ₹1,078.30, with a market capitalisation of ₹1,08,502 Cr.
Zydus Lifesciences Ltd operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Zydus Lifesciences Ltd has a P/E of 21.5 and a return on equity of 18.32%.